Richard C. Young & CO. LTD. increased its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 5.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 391,313 shares of the company's stock after purchasing an additional 18,925 shares during the quarter. Richard C. Young & CO. LTD.'s holdings in Kenvue were worth $8,355,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Grove Bank & Trust boosted its stake in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Kenvue during the 4th quarter valued at $29,000. Riverview Trust Co bought a new stake in shares of Kenvue in the 3rd quarter worth about $30,000. Fortitude Family Office LLC lifted its position in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares during the period. Finally, Ashton Thomas Securities LLC bought a new stake in Kenvue during the 3rd quarter worth approximately $35,000. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Trading Up 0.2 %
Shares of Kenvue stock traded up $0.05 on Wednesday, hitting $20.96. 10,316,961 shares of the company traded hands, compared to its average volume of 12,673,827. The stock's 50 day moving average price is $21.41 and its 200-day moving average price is $22.03. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a market cap of $40.19 billion, a PE ratio of 39.55, a PEG ratio of 2.16 and a beta of 1.45.
Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities research analysts predict that Kenvue Inc. will post 1.05 EPS for the current year.
Kenvue Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.91%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's dividend payout ratio is presently 154.72%.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the company. Royal Bank of Canada reaffirmed a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler raised Kenvue from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and cut their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Bank of America lifted their price target on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Finally, Citigroup cut their price objective on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $23.00.
Read Our Latest Report on KVUE
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
